About Me
Conditions and Treatments
Conditions
- abdominal tumor
- aids-related lymphoma
- aids-related malignancies
- anemia
- blood cancer
- breast cancer
- colorectal cancer
- gastrointestinal cancer
- kaposi sarcoma
- lung cancer
- lung carcinoma
- lymphoma
- malignant mesothelioma
- mediastinal tumor
- mesothelioma
- non-small cell lung cancer
- platelet disorder
- small cell lung cancer
- solitary fibrous tumor
- thoracic cancer
- thymus cancer
Learn more about conditions we treat at NYU Langone:
Liver Cancer & Liver Metastases , Stomach Cancer , AIDS-Related Lymphoma , Acute Lymphoblastic Leukemia , Acute Myeloid Leukemia , Chronic Lymphocytic Leukemia , Chronic Myelogenous Leukemia , Cutaneous T-Cell Lymphoma , Hairy Cell Leukemia , Myelodysplastic Syndromes , Myeloproliferative Disorders , Non-Hodgkin Lymphoma , Breast Cancer , Male Breast Cancer , Colorectal Cancer , Small Intestine Cancer , Kaposi Sarcoma , Lung Cancer , Non-Small Cell Lung Cancer , Small Cell Lung Cancer , Hodgkin Lymphoma , Primary Central Nervous System Lymphoma , Malignant Mesothelioma , Soft Tissue SarcomaCredentials
Positions
- Clinical Associate Professor, Department of Medicine at NYU Grossman School of Medicine
Board Certifications
- American Board of Internal Medicine (Medical Oncology), 1987
- American Board of Internal Medicine - Internal Medicine, 1986
Education and Training
- Fellowship, Memorial Sloan Kettering Cancer Center, Hematology/Oncology, 1988
- MD from Johns Hopkins University, 1980
Is this your profile?
Edit profileInsurance Plans Accepted
This provider accepts the following insurance plans.
-
Aetna
- Aetna HMO
- Aetna Indemnity
- Aetna Medicare
- Aetna POS
- Aetna PPO/EPO
-
Cigna
- Cigna EPO/POS
- Cigna PPO
-
Empire Blue Cross Blue Shield
- Empire Blue Cross Blue Shield EPO
- Empire Blue Cross Blue Shield HMO
- Empire Blue Cross Blue Shield Indemnity
- Empire Blue Cross Blue Shield MediBlue
- Empire Blue Cross Blue Shield POS
- Empire Blue Cross Blue Shield PPO
- Empire Blue Cross Blue Shield Pathways, Enhanced
-
GHI
- GHI CBP
-
HIP
- HIP Access I
- HIP Access II
- HIP Child Health
- HIP EPO/PPO
- HIP HMO
- HIP Medicare
- HIP POS
-
Local 1199
- Local 1199 PPO
-
MultiPlan/PHCS
- MultiPlan/PHCS PPO
-
Oxford
- Oxford Freedom
- Oxford Liberty
- Oxford Medicare
-
UHC
- UnitedHealthcare EPO
- UnitedHealthcare HMO
- UnitedHealthcare Medicare
- UnitedHealthcare POS
- UnitedHealthcare PPO
- UnitedHealthcare Top Tier
-
UPN
- UPN Elite
Locations and Appointments
Manhattan Hematology Oncology Associates
157 East 32nd Street, 2nd Floor, New York, NY 10016
Research My Research
Interests
hematologic abnormalities, Early and advanced cancer types , mycobacterial infections, hematologic growth factors
Research Interests Timeline
These focus areas and their associated publications are derived from PubMed and the MeSH term library.
*
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.
Publications
-
Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).
Lee, Hun Ju; Choi, Michael Y.; Siddiqi, Tanya; Wierda, William G.; Claudia Barrientos, Jacqueline; Lamanna, Nicole; Goldenberg, Alec; Isufi, Iris; Tuscano, Joseph M.; Subbiah, Suki; Weihe, Elizabeth Kristine; Ianopulos, Xen; Breitmeyer, James Bradley; Hsu, Frank J.; Wang, Michael; Jamieson, Catriona Hm; Kipps, Thomas J.Journal of clinical oncology. 2020; 38(15):
-
Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
Lee, Hun Ju; Choi, Michael Y.; Siddiqi, Tanya; Wierda, William G.; Barrientos, Jacqueline C.; Lamanna, Nicole; Goldenberg, Alec; Isufi, Iris; Tuscano, Joseph; Subbiah, Suki; Koff, Jean L.; Leslie, Lori A.; Chung, Gina G.; Weihe, Elizabeth K.; Ianopulos, Xen; Breitmeyer, James B.; Hsu, Frank J.; Wang, Michael; Jamieson, Catriona; Kipps, Thomas J.Blood. 2020; 136:
-
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL
Choi, Michael Y.; Ghia, Emanuela M.; Siddiqi, Tanya; Wierda, William G.; Lee, Hun Ju; Barrientos, Jacqueline C.; Lamanna, Nicole; Goldenberg, Alec; Tzachanis, Dimitrios; Reid, Erin G.; Weihe, Elizabeth K.; Rassenti, Laura Z.; Isufi, Iris; Bieler, Stewart; Ianopulos, Xen; Breitmeyer, James B.; Jamieson, Catriona; Kipps, Thomas J.Blood. 2019; 134: